In 2005, several groups independently reported a valine to phenylalanine substitution mutation at amino acid 617 of Jak2, in a large percentage of myeloproliferative neoplasm (MPN) patients [10]–[14]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.